Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth
Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from positive early-stage results and rising product sales. The Israeli biopharmaceutical firm reported first-quarter revenues from product sales of $10 million, up 170% from a year earlier, driven largely by higher sales to Pfizer and Brazil's Fiocruz.
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with increasing royalties expected, and the company has achieved a debt-free status and profitability. PRX-115 shows promise for gout treatment, potentially outperforming KRYSTEXXA, while PRX-119 targets NETs but remains speculative.
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explained that this method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech space.
Protalix Biotherapeutics gains momentum: analysts see long-term upside
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's improving financial position and revenue outlook have analysts projecting further upside following the release of its full year 2024 results.
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, including a promising gout treatment candidate. The biopharmaceutical company recorded $53 million in product revenue for the year ended December 31, 2024, a 31% increase from $40.4 million in 2023, with gains from sales to Chiesi, Pfizer, and Brazil.
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
On Monday, Protalix BioTherapeutics, Inc. PLX reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent.
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright John Vandermosten - Zach's SCR Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call.
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum
For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting rare diseases with cutting-edge treatments. The New Jersey- and Israel-based company has emerged as a biotech underdog with strong tailwinds that analysts at HC Wainwright and Zacks Small Cap Research believe puts it the brink of sustainable profitability.
Protalix Biotherapeutics gains momentum in the rare disease space: analysts
Protalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see sustainable profitability on the horizon. Strong revenue growth from its flagship Fabry disease treatment, Elfabrio, and a robust pipeline have prompted price target increases, with HC Wainwright raising its outlook to $15 per share and Zacks maintaining a valuation of $14.
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Investment Research Daniel Smith - H.C. Wainwright & Co., LLC Robert Sassoon - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2024 Financial and Business Results Conference Call.
Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors Dror Bashan - President and CEO Eyal Rubin - SVP and CFO Conference Call Participants John Vandermosten - Zacks Small Cap Research Unidentified Analyst - H.C. Wainwright Operator Good morning, ladies and gentlemen and welcome to the Protalix BioTherapeutics Second Quarter 2024 Financial and Business Results Conference Call.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders. Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a current trading price of below $1.25 per share, a decline of over 61% in value.
